ivpumps

Ivenix, Inc. Names Jorgen B. Hansen as Chief Executive Officer
Medical device and healthcare industry leader joins Ivenix to lead smart infusion pump commercialization

  • BOSTON, Jan 13, 2020 — Ivenix, Inc. today announced the appointment of Jorgen B. Hansen as CEO and a member of Ivenix’s board of directors. Hansen has more than 25 years of global healthcare experience.The CEO appointment comes at a time of great momentum for Ivenix, which received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2019. The infusion system was cleared under the FDA’s new regulatory guidance, adopted in 2014 to address recurring safety problems associated with existing infusion pumps.“We are thrilled to have someone of Jorgen’s caliber leading Ivenix as we build our business and execute our market launch,” said Ivenix Board Chairman John Douglass. “Jorgen brings extensive market knowledge, strategy, product and business development experience at this important time in the company’s evolution. He is a proven medical technology leader with deep expertise in commercialization strategies that successfully drive company growth.”…READ MORE
abide

Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s

  • Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
  • Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s  (exploratory phase IIa) and neuropathic pain (phase I)
  • Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones

Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE

double exposure image of virtual human 3dillustration on blue circuit board background represent artificial 
intelligence AI technology

Prealize Wins MedTech Breakthrough Innovation Award for Second Consecutive Year

PALO ALTO, Calif.April 29, 2020 /PRNewswire/ — Prealize, an artificial intelligence (AI)-enabled health insights company, today announced that, for the second straight year, it was selected as a winner of the Innovation in Healthcare Analytics Award, presented as part of the 2020 MedTech Breakthrough Awards program. In its fourth year, this program recognizes top companies, people, platforms and products in the health, fitness and medical technology industries today.

Prealize, which was known as Cardinal Analytx Solutions until it rebranded in January 2020, supports delivery of proactive healthcare by leveraging the power of AI and machine learning (ML) to identify not only patients at rising risk of health changes, but also the timing and key drivers of that risk.. READ MORE

Telemedicine

New Study by Teladoc Health Reveals COVID-19 Pandemic’s Widespread Negative Impact on Mental Health

Purchase, NY, May 6, 2020 – A new study by Teladoc Health highlights the widespread negative mental health impact of the COVID-19 pandemic, the corresponding growing proactive support by employers to help meet the need, and the increased interest and comfort in virtual care options as part of American’s mental health and wellness. The study of 1558 employees (or those recently employed) in the U.S. and Canada, was conducted in mid-April by study, marketing research and analytics firm, Leger which was commissioned by global virtual care leaders, Teladoc Health (NYSE: TDOC), as a follow up to the company’s 2019 international mental health study conducted last fall by Ipsos MORI.

COVID-19 Negative Impact More Prevalent in Women and Young Americans…READ MORE

vitals

Sapphire Digital Partners with Vim for Integrated Online Appointment Scheduling and Provider Engagement

LYNDHURST, N.J.–(BUSINESS WIRE)–Sapphire Digital, a leader in empowering consumers to make better choices that deliver health care savings, today announced a partnership with Vim, a leader in digital scheduling and EHR integrated provider referral guidance software. Together, the companies will provide an integrated end-to-end solution that allows consumers to shop for and schedule provider appointments online and allow providers to view member incentives in the EHR…READ MORE

download

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases – May 19, 2020

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases Multi-Target Collaboration Leverages Vividion’s Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments SAN DIEGO, CA, May 19, 2020 – Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at different stages of development. E3 ligases are an important class of proteins responsible for directing target proteins to the proteasome for degradation. Small molecules directed to novel E3 ligases with potentially differentiated properties, such as tissue-restricted bioactivity or stronger target recognition, have the potential to unlock a wide range of valuable therapeutic applications.

READ MORE

Scroll to top